Dengue vaccine safety in people with autoimmune rheumatic diseases
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 59 years old.
- You have a diagnosed autoimmune rheumatic disease (e.g., rheumatoid arthritis, lupus) that has been stable for at least 3 months.
- You are on no immune-suppressing drugs or only certain low-dose ones (like hydroxychloroquine, low-dose prednisone, methotrexate up to 20 mg/week).
- You have not received any dengue vaccine before.
- You are not pregnant, breastfeeding, or planning pregnancy for at least 3 months after vaccination.
- You have no history of cancer, HIV, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with certain rheumatic conditions (like arthritis, lupus, or vasculitis) and for healthy volunteers. It aims to learn more about these diseases and improve how they are treated.
This trial tests a new medicine, S-4321, for people with various autoimmune conditions like rheumatoid arthritis, psoriasis, eczema, or lupus. It aims to see if the drug is safe and can help control the overactive immune system.
This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.
This study tests the recombinant shingles vaccine in adults with autoimmune rheumatic diseases who are on certain mild medications. It aims to see if the vaccine is safe and effective for them.
This trial tests a new dengue vaccine in adults aged 40 to 79 to see if it can protect them from dengue fever. If you are generally healthy and willing to follow the study schedule, you may be able to join.
This trial tests an experimental dengue vaccine in healthy children and teens to see if it can prevent dengue. It may help protect your child from this mosquito-borne illness.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.